Document is current
Any future updates will be listed below
-
Authors
Lareau, Caleb A. https://orcid.org/0000-0003-4179-4807
Dubois, Sonia M. https://orcid.org/0000-0002-3169-2893
Buquicchio, Frank A.
Hsieh, Yu-Hsin
Garg, Kopal
Kautz, Pauline https://orcid.org/0000-0002-9658-1676
Nitsch, Lena
Praktiknjo, Samantha D. https://orcid.org/0000-0002-0186-5271
Maschmeyer, Patrick
Verboon, Jeffrey M.
Gutierrez, Jacob C.
Yin, Yajie https://orcid.org/0000-0002-2220-005X
Fiskin, Evgenij
Luo, Wendy
Mimitou, Eleni P. https://orcid.org/0000-0001-9737-6394
Muus, Christoph
Malhotra, Rhea
Parikh, Sumit
Fleming, Mark D. https://orcid.org/0000-0003-0948-4024
Oevermann, Lena
Schulte, Johannes https://orcid.org/0000-0003-0671-1201
Eckert, Cornelia
Kundaje, Anshul https://orcid.org/0000-0003-3084-2287
Smibert, Peter https://orcid.org/0000-0003-0772-1647
Vardhana, Santosha A. https://orcid.org/0000-0002-3100-1298
Satpathy, Ansuman T. https://orcid.org/0000-0002-5167-537X
Regev, Aviv https://orcid.org/0000-0003-3293-3158
Sankaran, Vijay G. https://orcid.org/0000-0003-0044-443X
Agarwal, Suneet https://orcid.org/0000-0003-4910-3118
Ludwig, Leif S. https://orcid.org/0000-0002-2916-2164
- License Information
-
More Information
Article History
Received: 21 January 2022
Accepted: 24 May 2023
First Online: 29 June 2023
Competing interests
: The Broad Institute has filed for a patent relating to the use of the technology described in this paper where C.A.L., L.S.L., C.M., A.R. and V.G.S. are named inventors (US provisional patent application 62/683,502). C.A.L. and L.S.L. are consultants to Cartography Biosciences. ATS is a founder of Immunai and Cartography Biosciences and receives research funding from Allogene Therapeutics and Merck Research Laboratories. A.R. is a founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas Therapeutics, and until August 31, 2020, was an SAB member of Syros Pharmaceuticals, Neogene Therapeutics, Asimov and ThermoFisher Scientific. Since August 1, 2020, A.R. has been an employee of Genentech. V.G.S. serves as an advisor to and/or has equity in Branch Biosciences, Novartis, Forma, Cellarity and Ensoma. S.A.V. is an advisor to Immunai and has provided consulting services to Koch Disruptive Technologies and ADC Therapeutics. The remaining authors declare no competing interests.
